EF
ALXN

Empirical Finance’s Alexion Pharmaceuticals ALXN Stock Holding History

Empirical Finance’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,828
Closed -$1.25M – 439
2021
Q2 		$1.25M Sell
6,828
-4,253
-38% -$730K 0.2% 104
2021
Q1 		$1.73M Hold
11,081
– – 0.3% 88
2020
Q4 		$1.73M Buy
11,081
+198
+2% +$25.4K 0.3% 88
2020
Q3 		$1.25M Buy
+10,883
New +$1.17M 0.27% 99
2017
Q1 		– Sell
-87
Closed -$11K – 624
2016
Q4 		$11K Buy
+87
New +$10.6K 0.01% 359

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Empirical Finance's ALXN Position: Q3 2021 in Review

Empirical Finance sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6,828 shares — an estimated $1.25M sold.

Empirical Finance first reported a position in ALXN in Q4 2016 and held it in 5 quarters. The position peaked at $1.73M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Empirical Finance reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Empirical Finance sold 6,828 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.25M.
  • Empirical Finance first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • Empirical Finance's Alexion Pharmaceuticals position peaked at $1.73M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Empirical Finance's 13F filing for Q3 2021, filed 12 Nov 2021.